- Push-out Score determined
- After almost eight years in the position
- Praise and thanks for Albers
- Kate Haviland taking over
- Albers will remain as Executive Chairman at Blueprint
- Albers spoke at length and said 187 words
(exechange) — Cambridge, Massachusetts, January 5, 2022 — Jeff Albers, chief executive of Blueprint, leaves his position. As announced by Blueprint Medicines Corp. in a news release and in a regulatory filing published on Wednesday, January 5, 2022, Jeffrey W. (Jeff) Albers leaves his post as chief executive officer at the precision therapy company, after almost eight years in the role, effective April 4, 2022.
Jeff Albers’s duties as CEO will be taken over by Kathryn (Kate) Haviland, currently Chief Operating Officer at Blueprint Medicines Corp.
“The culmination of a thoughtful, long-term succession planning process”
Jeff Albers’s departure from the CEO post is explained as follows. Alexis Borisy, co-founder and member of the Board of Directors of Blueprint Medicines, said: “The Board’s selection of Kate as our next CEO is the culmination of a thoughtful, long-term succession planning process that was led by Jeff and the Board and purposefully designed to drive the company’s continued success, ensure continuity, and empower our strong executive team.”
Albers will remain as Executive Chairman at Blueprint
“Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that its Board of Directors has appointed Kate Haviland to succeed Jeff Albers as Chief Executive Officer (CEO), effective April 4, 2022. At that time, Mr. Albers will transition from his current role as Chairman, President and CEO to Executive Chairman of the Board of Directors and Ms. Haviland will transition from her current role as Chief Operating Officer (COO) to President and CEO,” Blueprint said.
Blueprint said: “[E]ffective April 4, 2022 (the “Transition Date”), Jeffrey Albers will transition from his role as Chief Executive Officer and President of the Company and will become Executive Chairman.”
Share price increase since January 2017
The announcement follows an increase in Blueprint Medicines Corp.’s share price of 270% since January 2017.
In the position of CEO since 2014
Jeff Albers became CEO of the Company in 2014.
As part of the succession plan, Albers has agreed to serve as Executive Chairman through the end of 2022, with continued service as Chairman thereafter, with the goal of enabling a seamless leadership transition as the company continues to execute on its growth strategy.
Jeffrey W. Albers has served as the Company’s president and chief executive officer and a member of the Company’s board of directors since July 2014.
In addition, Albers has served on the board of directors since July 2017 and is currently serving on the compensation committee of Magenta Therapeutics, Inc.
Albers also has served on the board of directors since September 2020 and is currently serving on the compensation committee of Kymera Therapeutics, Inc.
Albers has over 15 years of experience in leadership roles in the biopharmaceutical industry.
Prior to joining the Company, from January 2012 to April 2014, he was president of Algeta ASA, or Algeta, a Norwegian biopharmaceutical company, where he was a member of the management team and oversaw the U.S. commercial and business functions.
Prior to Algeta, from July 2005 to November 2011, Albers was at Genzyme Corporation, or Genzyme, a biotechnology company that is now a wholly-owned subsidiary of Sanofi S.A., most recently as vice president of the U.S. hematology and oncology business unit.
Albers received a B.S. from Indiana University and an M.B.A. and a J.D. from Georgetown University.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Jeff Albers’s move on a scale of 0 to 10.
exechange reached out to Blueprint and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 2.2022 ($).